This trial is active, not recruiting.

Condition amyotrophic lateral sclerosis
Sponsor Centre Hospitalier Universitaire de Nīmes
Start date March 2014
End date June 2017
Trial size 800 participants
Trial identifier NCT02893605, AOI/2014/KM-01


This is a case-control study performed on a biological collection. The polymorphisms present on a pre-defined list of genes will be studied for 400 Amyotrophic Lateral Sclerosis (sporadic type) DNA samples and 400 control DNA samples.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective retrospective
Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
Controls correspond to spouses/partners of patients.

Primary Outcomes

The polymorphisms occurring on a pre-defined set of genes
time frame: Day 0 (transversal study)

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - The primary inclusion criterium is the same for that of the parent biological collection, i.e. the patients fulfill requirements for probable or definite Amyotrophic Lateral Sclerosis as defined by revised international criteria (Brooks et al 2000). - Additionally, included patients were followed-up by doctors at the University Hospital of Montpellier, thus enabling verification of Amyotrophic Lateral Sclerosis criteria over time. Exclusion Criteria: - The patient has a familial form of Amyotrophic Lateral Sclerosis (autosomic dominant or recessive types) with or without a mutation of one of the 3 genes known to be responsible for familial forms (SOD1, TARDBP, FUS). See Bender (1998).

Additional Information

Official title Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis
Principal investigator Kevin Mouzat, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes.